Author:
Silpa-archa Narumol,Likittanasombat Surachanee,Apinuntham Chalermkwan,Pruksaeakanan Chutipon,Charoenpipatsin Norramon,Chaiyabutr Chayada,Wongpraparut Chanisada
Abstract
AbstractBimatoprost ophthalmic solution 0.03% (PGF2α analogues) combined with narrowband ultraviolet B (NB-UVB) was reported to be an effective treatment for vitiligo. To investigate the efficacy and safety of treatment for non-segmental/segmental vitiligo compared among bimatoprost ophthalmic solution 0.01% combined with NB-UVB phototherapy, bimatoprost monotherapy, and placebo. This single-blind randomized controlled study enrolled stable Thai vitiligo patients with at least three similarly sized lesions in the same anatomical area. The treatment duration was 6 months with 1- and 2-month post-treatment follow-ups. The 3 selected lesions on each patient were randomized to receive combination therapy, monotherapy, or placebo. The Vitiligo Area Scoring Index (VASI) was used to evaluate lesion response. Of the 25 initially enrolled subjects, 19 patients were analyzed. There were 13 and 6 non-segmental and segmental vitiligo cases, respectively. Eight and 11 cases had face/neck and non-face/neck lesions, respectively. Non-segmental vitiligo and non-face/neck vitiligo patients in the combination group had significant improvement in VASI score at 3 months, 6 months, and at the 2-month follow-up. No side effects were observed/reported. Bimatoprost combination therapy was shown to be safe and effective for treating Thai patients with non-segmental vitiligo in non-face/neck areas of the body.
Publisher
Springer Science and Business Media LLC
Reference20 articles.
1. Taïeb, A. & Picardo, M. The definition and assessment of vitiligo: A consensus report of the Vitiligo European Task Force. Pigment Cell Res. 20, 27–35. https://doi.org/10.1111/j.1600-0749.2006.00355.x (2007).
2. Zhang, X. J. et al. Characteristics of genetic epidemiology and genetic models for vitiligo. J. Am. Acad. Dermatol. 51, 383–390. https://doi.org/10.1016/j.jaad.2003.12.044 (2004).
3. Le Poole, I. C., van den Wijngaard, R. M., Westerhof, W. & Das, P. K. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am. J. Pathol. 148, 1219–1228 (1996).
4. Ongenae, K., Van Geel, N. & Naeyaert, J. M. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 16, 90–100. https://doi.org/10.1034/j.1600-0749.2003.00023.x (2003).
5. Taieb, A. et al. Guidelines for the management of vitiligo: The European Dermatology Forum consensus. Br. J. Dermatol. 168, 5–19. https://doi.org/10.1111/j.1365-2133.2012.11197.x (2013).
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献